The FDA approved Kapvay (clonidine hydrochloride extended -release) as a monotherapy and adjunctive therapy for the treatment of attention- deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.
Caryn Belisle, RPh, Alka Patel, PharmD
Advertisement
Articles by Caryn Belisle, RPh, Alka Patel, PharmD
Advertisement
Latest Updated Articles
- Shionogi Pharma's Kapvay
March 14th 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5